 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- || B4T2-001 / Bio4T2
Enrollment closed, CAR T-Cell Therapy, Metastases: A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors (clinicaltrials.gov) - Oct 12, 2023
P1, N=36, Active, not recruiting, Sponsor: Shanghai East Hospital
Recruiting --> Active, not recruiting
- || B4T2-001 / Bio4T2
New P1 trial, Metastases: Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors (clinicaltrials.gov) - Oct 9, 2023
P1, N=24, Recruiting, Sponsor: Shanghai East Hospital
- B4T2-001 / Bio4T2
Selective recognition of over-expressed self-antigens in solid tumors using calibrated CAR-T therapy. (On Demand | Hall A; Poster Bd # 382) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2309;
P1
This is a novel target for T-cell therapy and is at elevated levels on multiple different types of solid tumors. BT-001 participates in pathobiology, tumor invasion as well as metastasis, and level of expression inversely correlates with overall survival.
- | B4T2-001 / Bio4T2
New P1 trial, CAR T-Cell Therapy, Metastases: A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors (clinicaltrials.gov) - Nov 18, 2022
P1, N=36, Recruiting, Sponsor: Shanghai East Hospital